Report of eight cases of pulmonary actinomycosis and their treatment with imipenem-cilastatin
- PMID: 10394825
Report of eight cases of pulmonary actinomycosis and their treatment with imipenem-cilastatin
Abstract
Studies on the efficacy of antimicrobial agents against actinomycosis in vivo have been limited apart from those involving penicillin. A prospective ministudy on the efficacy of imipenem-cilastatin in the treatment of pulmonary actinomycosis was performed based on preliminary encouraging in vitro and in vivo data. Eight patients were diagnosed as having pulmonary actinomycosis using fibreoptic bronchoscopy (7) and percutaneous transthoracic needle biopsy (1) in the authors' unit between 1994 and 1996. Each patient received a 4-week course of imipenem-cilastatin that comprised 2 weeks of intravenously administered drug (500 mg at 8-hourly intervals) and 2 weeks of intramuscularly administered drug (500 mg at 12-hourly intervals). Seven patients showed a very good clinical and radiographic response as well as bronchoscopically-documented treatment success. Treatment failed in one patient. Amongst the former group, one patient was lost to follow-up, another relapsed 3 months after treatment cessation and the rest remained relapse-free when followed-up for 18-44 months (mean 30.2 months). Furthermore, all patients showed good clinical tolerance and no abnormal treatment-related laboratory findings. The favourable outcome for most patients in this mini-study suggest that a 4-week parenteral course of imipenem-cilastatin is an efficacious treatment for pulmonary actinomycosis. This antimicrobial regimen might be a promising alternative to the time-honoured long-course treatment with intravenous and oral penicillin.
Similar articles
-
Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin.J Chemother. 1998 Apr;10(2):114-21. doi: 10.1179/joc.1998.10.2.114. J Chemother. 1998. PMID: 9603636 Clinical Trial.
-
Imipenem/cilastatin as empirical treatment of severe infections in compromised patients.J Chemother. 1991 Jan;3 Suppl 1:208-12. J Chemother. 1991. PMID: 12041767 Clinical Trial.
-
How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients?Cancer. 1998 Jun 15;82(12):2449-58. Cancer. 1998. PMID: 9635539
-
[Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract].Minerva Urol Nefrol. 1995 Sep;47(3):147-56. Minerva Urol Nefrol. 1995. PMID: 8815553 Review. Italian.
-
Overall clinical utility of the intramuscular preparation of imipenem/cilastatin.Chemotherapy. 1991;37 Suppl 2:53-7. doi: 10.1159/000238920. Chemotherapy. 1991. PMID: 1879188 Review.
Cited by
-
Thoracic Actinomycosis: A Rare Occurrence.Infect Dis Rep. 2016 Mar 21;8(1):5963. doi: 10.4081/idr.2016.5963. eCollection 2016 Mar 21. Infect Dis Rep. 2016. PMID: 27103971 Free PMC article.
-
Pulmonary actinomycosis during the first decade of 21st century: cases of 94 patients.BMC Infect Dis. 2013 May 14;13:216. doi: 10.1186/1471-2334-13-216. BMC Infect Dis. 2013. PMID: 23672372 Free PMC article.
-
Pulmonary actinomycosis: a case undergoing resection through video-assisted thoracic surgery (VATS).J Zhejiang Univ Sci B. 2007 Oct;8(10):721-4. doi: 10.1631/jzus.2007.B0721. J Zhejiang Univ Sci B. 2007. PMID: 17910114 Free PMC article.